10-Q: Q2 2024 Earnings Report
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
10-Q: Q1 2024 Earnings Report
TenX Keane Acquisition Announces Contribution to Trust Account in Connection With Extension Amendment Proposal
Citius Pharmaceuticals Executes Definitive Agreement To Merge Wholly Owned Subsidiary With TenX Keane Acquisition To Form Publicly Listed Citius Oncology, Inc.
Express News | TenX Keane Acquisition Extends Deadline for Initial Business Combination
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
TenX Keane Acquisition Corp.'s (NASDAQ:TENKU) Lock-Up Period Will Expire on April 12th
Express News | News On TenX Keane Acquisition (TENKU) Now Under TENK
Reported Late Tuesday, TenX Keane Acquisition Announces The Separate Trading Of Its Ordinary Shares And Rights Commencing On December 8, 2022
TenX Keane Acquisition Announces the Separate Trading of Its Ordinary Shares and Rights Commencing on December 8, 2022
TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option
TenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering
TenX Keane Acquisition Announces Pricing of $60M Initial Public Offering
NASDAQ TRADE HALT CONTINUES TENKU.O REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TENKU.O REASON NOT AVAILABLE AT 03:59 AM
NASDAQ TRADE HALT TENKU.O REASON NOT AVAILABLE AT 07:05 AM
No Data
No Data